Pharmaceuticals, Biotechnology and Life Sciences
AFFiRiS AG, a clinical-stage biopharmaceutical company developing novel disease-modifying specific active immunotherapies (SAITs) for patients with neurodegenerative diseases, will proceed with the preparations for the planned phase 2 study and confirms its intended initiation in the US and Europe in the second half of 2020.
Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, has started dosing in a Phase 1b clinical study of LRRK2 inhibitor DNL151 in patients with Parkinson’s disease, and the launch of its Engage Parkinson’s website.
— Dr. Torsten Matthias appointed CEO, scientific founder Prof. Dr. Armin Giese joins as CSO —
— SERY technology in-licensed from Max-Planck Innovation GmbH to design next-generation candidate portfolio —
Funding in excess of US$1 million to support the development of a brain imaging probe for patient diagnosis and the…
ConvaTec Group, a UK-based medical products and technologies company, said on Monday that it has appointed two joint corporate brokers.
The research and innovation program of the European Union, Horizon 2020, has awarded a grant of approximately €6.0 million for…
Impax Laboratories has been granted by the European Commission (EC) authorization to market its Numient oral capsule formulation for the symptomatic treatment of adult patients with Parkinson’s disease.
Allergan, a Dublin-headquartered pharmaceutical company, confirmed on Monday that it has filed an Abbreviated New Drug Application (ANDA) with the…